$3.79
0.26% today
Nasdaq, Sep 30, 08:19 pm CET
ISIN
US29970R1059
Symbol
EVAX

Evaxion Biotech A/S - ADR Stock News

Positive
24/7 Wall Street
5 days ago
Shares of clinical-stage pharmaceutical company, Plus Therapeutics, are up about 31% on a volume spike of 216.4 million
Neutral
Seeking Alpha
5 days ago
Evaxion A/S - Special Call Company Participants Birgitte Rono - Interim CEO & Chief Scientific Officer Thomas Schmidt - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Kevin DeGeeter Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Divisio...
Neutral
GlobeNewsWire
5 days ago
COPENHAGEN, Denmark, September 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has out-licensed its vaccine candidate EVX-B3 to MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) as per the option and license agreement entered between the two companies in September 2024.
Neutral
Seeking Alpha
about one month ago
Evaxion A/S (EVAX) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Birgitte Rono - Interim CEO & Chief Scientific Officer Thomas Frederik Schmidt - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Operator Hello, and welcome to Evaxion's Second Quarter 2025 Conference Call. [Operator Instruc...
Neutral
GlobeNewsWire
about 2 months ago
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening of the Nasdaq CM.
Neutral
GlobeNewsWire
2 months ago
COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.
Neutral
GlobeNewsWire
3 months ago
COPENHAGEN, Denmark, July 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has finalized its agreement with the European Investment Bank (EIB) to convert debt into equity.
Neutral
GlobeNewsWire
3 months ago
COPENHAGEN, Denmark, July 1, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces several key executive management changes to optimize value from its proprietary AI-Immunology™ platform and pipeline.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today